Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
With our innovative techniques and many years of experience, Creative Biolabs can provide our clients in one-stop CAR development services. Through our advanced CAR construction and evaluation platform, our scientists are confident in TanCAR production with high efficiency and quality.
Chimeric antigen receptors (CARs) are artificial molecules that specificly direct to antigens. CAR, as a therapy for cancer, uses a technique called adoptive cell transfer. T cells are removed from a patient and modified so that they express receptor specificly to the patient's particular cancer. T cells targeting was mediated through molecules consisting of a target-antigen-specific antibody domain and signaling subunits of the Fc receptor or T cell receptor. Functional implication in CAR research field would likely translate into therapeutic benefits.
However, traditional CAR can't meet higher requirements. Commonly, downregulation or mutation of target antigens is observed in cancer cells, creating antigen-loss escape variants. With our experienced team and advanced technologies, Creative Biolabs has developed a kind of novel CAR. This novel CAR, in which two distinct antigen recognition domains are present in tandem on a single transgenic receptor, is named TanCAR. This design can enable simultaneous targeting of tumor cells and elements in the tumor microenvironment. Thereby, it can augment T cell activation and function by increasing avidity and broadening their therapeutic reach. Equipped with both facilitating synergistic activation and functionality, TanCARs have much important therapeutic implications.
After the construction of TanCAR, our scientists can offer you a series of services to complete your whole research, including but not limited to CAR cell in vitro assay, CAR preclinical in vivo assay and CAR clinical trials.
Based on our state-of-the-art technology and expertise, Creative Biolabs are remarkable in the construction of tandem Chimeric antigen receptors. Our scientists are pleased to offer customized services to meet your specific demands. If you are interested in our service, please contact us for more details. We will get back to you soon.
Fig.1 Designing a Bispecific TanCAR Molecule.
Reference
Zakaria Grada, et al. TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Molecular Therapy, 2013, 2, e105.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
